Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

Zepbound is FDA-approved for weight loss in adults with obesity or overweight who have a weight-related condition. The side effects of semaglutide are quite similar to those of tirzepatide ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

The FDA has approved Wegovy to reduce heart attack ... the three doctors say they’re comfortable prescribing semaglutide long-term for weight loss for a patient eligible for the medication.

Among those who adhered to treatment, the high-dose group achieved an average weight loss of 20.7% ... as it was first approved in 2022, while semaglutide has been on the market since 2017.

The US Food and Drug Administration (FDA) has declared an end to the ... Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival ...

The FDA approved Ospomyv and Xbryk, denosumab biosimilars that could expand access to treatment for osteoporosis, cancer-related bone loss ... The latest semaglutide (Ozempic; Novo Nordisk ...